MarginsXMarginsX
Home › Markets › Health Care › HCWB

HCW Biologics Inc. (HCWB)

HCWB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.8000
+3.48% on the day
Market cap
$1.8M
Nano cap
Revenue · 2025
$54K
-97.9% on 2024
Net income · 2025
-$8.0M
-14677.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1828673/000119312526134934/0001193125-26-134934-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerHCWB on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001828673
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$54K
Net income-$8.0M
Operating income-$13.2M
Net margin-14677.1%
Operating margin-24270.7%
Revenue growth-97.9%
Cash$2.0M
Total assets$24.5M
P/E (computed)Net income was not positive
P/S (computed)33.0×

Warning signs

Cash runway
0.7 months
$741K cash at June 30, 2026
Share count, 1 year
+412.1%
2025-08-12 to 2026-08-14 · +1126.7% over 3 years
Going-concern doubt
Yes
10-Q filed August 14, 2026
Insider net buying, 12 months
$512K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors raise substantial doubt regarding the Company's ability to continue as a going concern. 6 The accompanying condensed financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business."
10-Q 2026-08-14
Cash and burn$741K cash; operating cash flow -$3.0M a quarter.Report 2026-06-30
Shares outstanding1,836,324 (2026-08-14); 2,151,607 a year earlier; 35,926,721 three years earlier. 1y figure adjusted for splits (1-for-6 overall); 3y figure adjusted for splits (1-for-240 overall).Cover page 2026-08-14
Reverse splits, 3 years2; latest 1-for-6 on 2026-06-30Source 2026-06-30
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-06-01
AuditorCrowe LLP, Indianapolis, Indiana, United StatesPCAOB Form AP 2026-04-09
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $512K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$122K-$5.2M-$4.0M$741K$6.6M$6.7M10-Q 2026-08-14
Q1 2026
2026-03-31
$6.5M$3.5M-$1.6M$1.2M$6.6M$6.5M10-Q/A 2026-08-14
Q4 2025
2025-12-31
$27K$719K-$3.4M$2.0M$6.8M$54K10-K 2026-03-31
Q3 2025
2025-09-30
$16K-$4.6M-$3.2M$1.1M$6.8M$422K10-Q 2025-11-14
Q2 2025
2025-06-30
$7K-$1.9M-$3.3M$2.4M$6.8M$833K10-Q 2026-08-14
Q1 2025
2025-03-31
$5K-$2.2M-$3.5M$1.1M$13.9M$1.4M10-Q/A 2026-08-14
Q4 2024
2024-12-31
$395K-$3.4M-$2.8M$4.7M$13.7M$2.6M10-K 2026-03-31
Q3 2024
2024-09-30
$426K-$3.9M-$2.9M$998K$12.8M$3.5M10-Q 2025-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-12026-10-02
Latest annual report10-K2026-03-31
Latest quarterly / interim10-Q2026-08-14
Latest current report8-K2026-11-16
Latest proxyDEF 14A2026-10-01

Source: SEC EDGAR submissions feed, 342 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-24.2%
1 month-38.7%
3 months-73.6%
Year to date-86.7%
1 year-94.8%
From 52-week high-95.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
SXTP60 Degrees Pharmaceuticals Inc.$0.4938-4.65%$1.7M
ENLVEnlivex Ltd.$1.12-5.88%$1.7M
XRTXXORTX Therapeutics Inc. Common Shares$1.04-5.45%$1.9M
ONCOOnconetix Inc.$2.91-9.35%$1.9M
PPCBPropanc Biopharma Inc.$1.89-2.62%$2.0M
ARTLArtelo Biosciences Inc.$1.70-17.87%$1.6M
CMNDClearmind Medicine Inc. Common Shares$4.18-7.67%$2.1M
SBFMSunshine Biopharma Inc.$2.60-3.70%$2.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier